Novel BRAF Inhibitor Drugs to Overcome Challenges of First Generation BRAF Inhibitor Drugs

Release Date: 23-Nov-2020

Patients having altered BRAF gene are now aligned towards getting a novel drug designed to treat the cancer. An important role of the BRAF gene is to inform the healthy cells to grow and transform into new cells but the gene is also responsible for the development of cancers. Although BRAF inhibitors have been developed by the researchers for the treatment of the cancers but all the BRAF inhibitors are not observed to be working efficiently in the patients.

The researchers are now focused at novel drug called as PLX8394, which is designed to treat the patients who have developed resistance against different types of drugs and with wider range of BRAF inhibitors. The clinical research study involves treatment of 75 patients with investigational compound PLX8394 with cobicistat. It was reported by the researchers that the addition of the other drug i.e. cobicistat resulted in doubling the level of PLX8394 in the blood. It was observed that out of 45 patients who received both the drugs, 22% showed partial response.

The primary aim of the development of next-generation BRAF inhibitors was to overcome the limitation of the first-generation BRAF inhibitors, which was although received by the researchers as the results came out to be safe and effective for a group of people. The next few stages of the clinical research study will be for studying and verifying the optimum dose of the drugs for maximum number of patients. The whole clinical research study concluded that the next generation BRAF inhibitors were promising and effective against different types of cancer, leading to a conclusion that the next few years of the outcome will be responsible for completely transforming the cancer therapeutics sector.